Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: A systematic review

Journal of Ovarian Research

Volumn 7, Issue 1, 2014, Pages

  Aravantinos, Gerasimos ^a   Pectasides, Dimitrios ^b  

^a Agioi Anargiroi Hospital   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Angiogenesis; Bevacizumab; Fallopian tube cancer; Ovarian cancer; Primary peritoneal cancer; Targeted therapies

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BIOLOGICAL MARKER; CA 125 ANTIGEN; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FIBROBLAST GROWTH FACTOR 2; GEMCITABINE; IMATINIB; NINTEDANIB; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PERIFOSINE; PLACEBO; PLATELET DERIVED GROWTH FACTOR BB; SORAFENIB; SUNITINIB; TOPOTECAN; TREBANANIB; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 1; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABSCESS; ADVANCED CANCER; ARTERIAL THROMBOEMBOLISM; BLEEDING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM BLEEDING; CONGESTIVE HEART FAILURE; CYTOREDUCTIVE SURGERY; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEBRILE NEUTROPENIA; FISTULA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; MALIGNANT ASCITES; META ANALYSIS; MULTICENTER STUDY (TOPIC); NEUTROPENIA; OVARY CANCER; PAIN; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT; DIET THERAPY; FEMALE; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); OVARIAN NEOPLASMS; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84901635787     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-7-57     Document Type: Review

References (70)

1. Angiogenesis inhibitors for the treatment of ovarian cancer (review). Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S, Morrison J, Cochrane Database Syst Rev 2011 9 CD007930
2. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
3. Revised FIGO staging for gynaecological cancer. Shepherd JH, Br J Obstet Gynaecol 1989 96 889 892 10.1111/j.1471-0528.1989.tb03341.x 2775686
4. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, Sessa C, Castiglione M, ESMO Guidelines Working Group, Ann Oncol 2010 21 Suppl. 5 2223 v30 20555088
5. Ovarian cancer. Hennessy BT, Coleman RL, Markman M, Lancet 2009 374 1371 1382 10.1016/S0140-6736(09)61338-6 19793610
6. Therapeutic strategies in epithelial ovarian cancer. Kim A, Ueda Y, Naka T, Enomoto T, J Exp Clin Cancer Res 2012 31 14 10.1186/1756-9966-31-14 22330607
7. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K, Japanese Gynecologic Oncology Group, Lancet 2009 374 1331 1338 10.1016/S0140-6736(09)61157-0 19767092
8. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomized, controlled, open-label trial. Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S, Terauchi F, Sugiyama T, Ochiai K, Japanese Gynecologic Oncology Group, Lancet Oncol 2013 14 1020 1026 10.1016/S1470-2045(13)70363-2 23948349
9. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F, et al. Lancet Oncol 2014 15 396 405 10.1016/S1470-2045(14)70049-X 24582486
10. Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). Chan J, Brady M, Penson R, Monk B, Boente M, Walker J, Davidson S, DiSilvestro P, O'Malley D, Morgan M, Pearl M, De Geest K, Michael H, Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology, Liverpool, UK, October 19-22, 2013
11. Clinical Practice Guidelines in Oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer. National Comprehensive Cancer Network, Version 1.2013. [ http://www.nccn.org/professionals/physician- gls/pdf/ovarian.pdf ]. Accessed 01.02.13
12. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U, Int J Gynaecol Obstet 2006 95 Suppl. 1 161 S192 17161157
13. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to non-platinum doublets and adding anti-angiogenesis compounds. Monk BJ, Coleman RL, Int J Gynecol Cancer 2009 19 Suppl. 2 63 S67 19955917
14. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Masoumi Moghaddam S, Amini A, Morris DL, Pourgholami MH, Cancer Metastasis Rev 2012 31 143 162 10.1007/s10555-011- 9337-5 22101807
15. Role of vascular endothelial growth factor in ovarian physiology and pathology. Geva E, Jaffe RB, Fertil Steril 2000 74 429 438 10.1016/S0015- 0282(00)00670-1 10973633
16. Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer. Bandiera E, Franceschini R, Specchia C, Bignotti E, Trevisiol C, Gion M, Pecorelli S, Santin AD, Ravaggi A, ISRN Obstet Gynecol 2012 2012 245756 22792477
17. VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5. Herr D, Sallmann A, Bekes I, Konrad R, Holzheu I, Kreienberg R, Wulff C, Gynecol Oncol 2012 127 210 216 10.1016/j.ygyno.2012.05.002 22579791
18. Angiogenesis in normal and neoplastic ovaries. Ramakrishnan S, Subramanian IV, Yokoyama Y, Geller M, Angiogenesis 2005 8 169 182 10.1007/s10456-005-9001-1 16211363 (Pubitemid 41712846)
19. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Ferrara N, Hillan KJ, Novotny W, Biochem Biophys Res Commun 2005 333 328 335 10.1016/j.bbrc.2005.05.132 15961063 (Pubitemid 40848295)
20. STAC: A phase II study of carboplatin/paclitaxel/bevacizumab followed by randomization to either bevacizumab alone or erlotinib and bevacizumab in the upfront management of patients with ovarian, fallopian tube or peritoneal cancer [abstract]. Campos S, Atkinson T, Berlin S, Roche M, Whalen C, Matulonis U, Horowitz N, Birrer M, Penson R, Gynecol Oncol 2011 120 79 S181
21. Incorporation of bevacizumab in the primary treatment of ovarian cancer. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX, Gynecologic Oncology Group, N Engl J Med 2011 365 2473 2483 10.1056/NEJMoa1104390 22204724
22. A phase 3 trial of bevacizumab in ovarian cancer. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM, ICON7 Investigators, N Engl J Med 2011 365 2484 2496 10.1056/NEJMoa1103799 22204725
23. ICON7: Final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer [abstract]. Oza AM, Perren TJ, Swart AM, Schröder W, Pujade-Lauraine E, Havsteen H, Beale P, Cervantes AM, Embleton AC, Parmar M, E J Cancer 2013 49 2 BA:6
24. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR, J Clin Oncol 2012 30 2039 2045 10.1200/JCO.2012.42.0505 22529265
25. Updated overall survival analysis in OCEANS, a randomized phase 3 trial of gemcitabine (G) + carboplatin (C) and bevacizumab (BV) or placebo (PL) followed by BV or PL in platinum-sensitive recurrent epithelial ovarian (ROC), primary peritoneal (PPC), or fallopian tube cancer (FTC) [abstract]. Aghajanian C, Nycum LR, Goff B, Nguyen H, Husain A, Blank SV, Presented at the ESMO Congress, Vienna, Austria, 28 September-2 October 2012. Abstract 9670
26. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) [abstract]. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote IB, Witteveen P, Bamiaset A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag DT, Ray-Coquard I, and AURELIA Investigators, J Clin Oncol 2012 30 Suppl. 18 LBA5002
27. Final overall survival (OS) results from AURELIA, an open-label randomised phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer (OC) [abstract]. Witteveen P, Lortholary A, Fehm T, Poveda A, Reuss A, Havsteen H, Raspagliesi F, Vergote I, Bamias A, Pujade-Lauraine, E J Cancer 2013 49 2 BA:5
28. Independent radiologic review of GOG218, a phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC) [abstract]. Burger RA, Brady MF, Rhee J, Sovak MA, Nguyen H, Bookman MA, J Clin Oncol 2011 29 Suppl. 15 5023
29. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM, Oza A, Perren T, Lancet Oncol 2013 14 236 243 10.1016/S1470- 2045(12)70567-3 23333117
30. Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC) [abstract]. Stockler MR, Hilpert F, Friedlander M, King M, Wenzel LB, Lee C, Joly F, Gregorio ND, Arija JAA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade Lauraine E, and AURELIA Investigators, J Clin Oncol 2013 31 5542
31. Carboplatin and paclitaxel or oxaliplatin and capecitabine, with or without bevacizumab, as first-line therapy in treating patients with newly diagnosed stage II, stage III, stage IV, or recurrent stage I epithelial ovarian cancer or fallopian tube cancer. National Cancer Institute, National Library of Medicine. http://www.clinicaltrials.gov/show/NCT01081262
32. Carboplatin and paclitaxel with or without bevacizumab after surgery in treating patients with recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer. National Cancer Institute, National Library of Medicine. http://www.clinicaltrials.gov/show/NCT00565851
33. Evaluation of optimal initial treatment duration of bevacizumab in combination with standard chemotherapy in patients with ovarian cancer (BOOST). AGO Study Group, National Library of Medicine. http://www.clinicaltrials.gov/ show/NCT01462890
34. Bevacizumab and intravenous or intraperitoneal chemotherapy in treating patients with stage II, stage III, or stage IV ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. National Cancer Institute, National Library of Medicine. http://www.clinicaltrials.gov/show/NCT00951496
35. Paclitaxel and carboplatin with or without bevacizumab in treating patients with stage II, stage III, or stage IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer. National Cancer Institute, National Library of Medicine. http://www.clinicaltrials.gov/show/NCT01167712
36. Safety of front-line bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC): Results from OCTAVIA [abstract]. Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore ME, Segalla JGM, Reyners AKL, Kovalenko N, Oaknin A, Selle F, Bollag DT, Pignata S, OCTAVIA Investigators, J Clin Oncol 2012 30 5017
37. Biomarker (BM) results from GOG-0218, a phase 3 trial of front-line bevacizumab (BV) + chemotherapy (CT) for ovarian cancer (OC) [abstract]. Birrer MJ, Lankes H, Burger RA, Mannel R, Homesley H, Henschel V, Sovak M, Scherer SJ, De Haas S, Pallaud C, Presented at the ESMO Congress, Vienna, Austria, 28 September-2 October 2012. Abstract 198P
38. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL, Alberts DS, Clin Cancer Res 2010 16 5320 5328 10.1158/1078-0432.CCR-10-0974 21041183
39. Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Madsen CV, Steffensen KD, Olsen DA, Waldstrøm M, Smerdel M, Adimi P, Brandslund I, Jakobsen A, J Ovarian Res 2012 5 23 10.1186/1757-2215-5-23 22989094
40. Study of clinical and biological prognostic factors in patients with ovarian cancer receiving carboplatin + paclitaxel with bevacizumab (MITO16/MANGO-2). National Cancer Institute, Naples, National Library of Medicine identifier: NCT01706120. Available from: http://www.clinicaltrials.gov/ show/NCT01706120. [Accessed 01.02.13]
41. An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer [abstract]. Aghajanian C, Blank SV, Goff BA, Judson PL, Nycum LR, Sovak MA, Yi J, Husain A, J Clin Oncol 2012 30 Suppl. 15 5054
42. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT, J Clin Oncol 2009 27 5601 5606 10.1200/JCO.2009.23.2777 19826113
43. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial [abstract]. Ledermann JA, Perren TJ, Raja FA, Embleton A, Rustin GJS, Jayson G, Kaye SB, Swart AM, Vaughan M, Hirte H, E J Cancer 2013 49 2 BA:10
44. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16) [abstract]. Du Bois A, Floquet A, Weon Kim J, Rau J, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Wimberger P, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Kim JH, Harter P, J Clin Oncol 2013 31 BA5503
45. A phase II trial of sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, Pereira L, Tyburski K, Roche M, Szymonifka J, Berlin S, Gynecol Oncol 2013 128 215 220 10.1016/j.ygyno.2012.07.126 22885865
46. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Biagi JJ, Oza AM, Chalchal HI, Grimshaw R, Ellard SL, Lee U, Hirte H, Sederias J, Ivy SP, Eisenhauer EA, Ann Oncol 2011 22 335 340 10.1093/annonc/mdq357 20705911
47. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Baumann KH, du Bois A, Meier W, Rau J, Wimberger P, Sehouli J, Kurzeder C, Hilpert F, Hasenburg A, Canzler U, Hanker LC, Hillemanns P, Richter B, Wollschlaeger K, Dewitz T, Bauerschlag D, Wagner U, Ann Oncol 2012 2 2265 2271
48. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ, J Clin Oncol 2011 29 69 75 10.1200/JCO.2009.26.7856 21098323
49. A randomized, double-blind, phase 2 trial of maintenance sorafenib in epithelial ovarian or primary peritoneal cancer. Herzog TJ, Scambia G, Kim BG, Lhommé C, Markowska J, Ray-Coquard I, Sehouli J, Colombo N, Shan M, Petrenciuc O, Oza A, Int J Gynecol Cancer 2012 22 Suppl. 3 99 E100
50. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, Earl H, Perren T, Gore M, Persic M, Adams M, James L, Temple G, Merger M, Rustin G, J Clin Oncol 2011 29 3798 3804 10.1200/JCO.2010.33.5208 21859991
51. AGO-OVAR 12: a randomized placebo-controlled GCIG/ENGOT-Intergroup phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer [abstract]. Du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, del Campo JM, Ottevanger P, Merger M, Harter P, Int J Gyn Cancer 2013 23 Suppl.1 BA1
52. Phase II multi-institutional study of docetaxel plus aflibercept (AVE0005, NSC# 724770) in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer [abstract]. Coleman RL, Duska LR, Ramirez PT, Modesitt SC, Schmeler KM, Iyer R, Garcia M, Sood A, J Clin Oncol 2011 29 Suppl. 15 5017
53. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Gotlieb WH, Amant F, Advani S, Goswami C, Hirte H, Provencher D, Somani N, Yamada SD, Tamby J-F, Vergote I, Lancet Oncol 2012 13 154 162 10.1016/S1470-2045(11)70338-2 22192729
54. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Colombo N, Mangili G, Mammoliti S, Kalling M, Tholander B, Sternas L, Buzenet G, Chamberlain D, Gynecol Oncol 2012 125 42 47 10.1016/j.ygyno.2011.11.021 22112608
55. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, Chambers SK, Ghatage P, Pippitt CH Jr, Brown JV 3rd, Covens A, Nagarkar RV, Davy M, Leath CA 3rd, Nguyen H, Stepan DE, Weinreich DM, Tassoudji M, Sun YN, Vergote IB, J Clin Oncol 2012 30 362 371 10.1200/JCO.2010.34.3178 22184370
56. A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer [abstract]: TRINOVA-1. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Navale L, Warner DJ, Oza AM, E J Can cer 2013 49 2 BA:41
57. TRINOVA-2: Trebananib in Ovarian Cancer-2. Amgen, National Library of Medicine. http://www.clinicaltrials.gov/show/NCT01281254
58. TRINOVA-3: A study of AMG 386 or AMG 386 placebo in combination with paclitaxel and carboplatin to treat ovarian cancer. Amgen, National Library of Medicine. http://www.clinicaltrials.gov/show/NCT01493505
59. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Verheul HM, Hammers H, van Erp K, Wei Y, Sanni T, Salumbides B, Qian DZ, Yancopoulos GD, Pili R, Clin Cancer Res 2007 13 4201 4208 10.1158/1078-0432.CCR- 06-2553 17634549 (Pubitemid 47105984)
60. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D, Carmeliet P, Cell 2007 131 463 475 10.1016/j.cell.2007.08.038 17981115 (Pubitemid 350007692)
61. BIBF 1120 in bevacizumab resistant, persistent, or recurrent epithelial ovarian cancer. Boehringer Ingelheim, National Library of Medicine. http://www.clinicaltrials.gov/show/NCT01669798
62. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor α and Aky inactivation. Matei D, Chang DD, Jeng M-H, Clin Cancer Res 2004 10 681 690 10.1158/1078-0432.CCR-0754-03 14760091 (Pubitemid 38174008)
63. Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer. Safra T, Andreopoulou E, Levinson B, Borgato L, Pothuri B, Blank S, Tiersten A, Boyd L, Curtin J, Muggia F, Anticancer Res 2010 30 3243 3247 20944093
64. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Sonpavde G, Hutson TE, Sternberg CN, Expert Opin Investig Drugs 2008 17 253 261 10.1517/13543784.17.2. 253 18230058 (Pubitemid 351578205)
65. Sorafenib. Hahn O, Stadler W, Curr Opin Oncol 2006 18 615 621 10.1097/01.cco.0000245316.82391.52 16988583 (Pubitemid 44427636)
66. Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: A randomized phase II study of the Sarah Cannon Research Institute [abstract]. Thompson DS, Dudley BS, Bismayer JA, Gian VG, Merritt WM, Whorf RC, Burris HA, Hainsworth JD, J Clin Oncol 2013 31 5113
67. Efficacy and safety of sorafenib added to topotecan in patients with platinum-resistant recurrent ovarian cancer: A NOGGO-AGO intergroup run-in-study (TRIAS). Chekerov R, Mahner S, Lorenz R, Hilpert F, Harter P, Wagner U, Klare P, Sehouli J, NOGGO-AGO Intergroup Study, Int J Gynecol Cancer 2011 21 597 10.1097/IGC.0b013e318214557c
68. Sorafenib and bevacizumab to treat ovarian, fallopian and peritoneal cancer. National Cancer Institute, National Library of Medicine. http://www.clinicaltrials.gov/show/NCT00436215
69. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM, Clin Cancer Res 2003 9 327 337 12538485 (Pubitemid 36109749)
70. Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials. Ye Q, Chen H-L, Arch Gynecol Obstet 2013 288 655 666 10.1007/s00404-013-2820-1 23543268